Smith & Nephew SNATS (NYSE:SNN) Downgraded to Buy Rating by Wall Street Zen

Smith & Nephew SNATS (NYSE:SNN) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

A number of other equities analysts have also recently issued reports on SNN. Weiss Ratings reissued a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Royal Bank Of Canada lowered Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. Finally, Canaccord Genuity Group upped their price target on Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a research report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $36.25.

Smith & Nephew SNATS Trading Down 1.3%

Shares of SNN opened at $31.92 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57. The company has a 50-day moving average price of $34.36 and a two-hundred day moving average price of $34.64. Smith & Nephew SNATS has a 12 month low of $23.91 and a 12 month high of $38.79.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of SNN. Garner Asset Management Corp acquired a new position in shares of Smith & Nephew SNATS in the 4th quarter worth approximately $27,000. Arax Advisory Partners grew its position in Smith & Nephew SNATS by 142.6% during the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 569 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in Smith & Nephew SNATS during the 4th quarter valued at $36,000. Caitong International Asset Management Co. Ltd bought a new position in Smith & Nephew SNATS in the 3rd quarter valued at $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Smith & Nephew SNATS in the 4th quarter valued at $43,000. Institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.